Showing 1191-1200 of 1635 results for "".
- National Glaucoma Research Foundation Survey Reveals Patients’ Experiences and Concerns During COVID-19https://modernod.com/news/national-glaucoma-research-foundation-survey-reveals-patients-experiences-and-concerns-during-covid-19/2478017/Glaucoma Research Foundation (GRF) announced results from a survey designed to explore glaucoma patients’ experiences and concerns during the COVID-19 pandemic-related shutdowns. The survey, conducted among patients in the GRF database and suppo
- EyePoint Pharmaceuticals Names Jay S. Duker, MD, Chief Strategic Scientific Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-names-jay-s-duker-md-chief-strategic-scientific-officer/2478005/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Strategic Scientific Officer. In this newly created role, Dr. Duker will lead the strategic advancement of our research and development efforts, beginning with our lead development candidate EYP-1901 for wet age-rela
- Oertli Instrumente Names New Director of the Boardhttps://modernod.com/news/oertli-instrumente-names-new-director-of-the-board/2477983/Andreas Bosshard, co-owner and former managing director of Oertli Instrumente AG, handed over the chairmanship of the board to Andreas Schmidheini. The reorganization became effective January 1, 2020. In 1988, Mr. Bosshard joined Oertli Instrumente AG and took over as managing director in
- VisionCare Names Thomas Ruggia as New Chief Executive Officerhttps://modernod.com/news/visioncare-names-thomas-ruggia-as-new-chief-executive-officer/2477973/VisionCare announced that Thomas Ruggia has been appointed as the company’s new Chief Executive Officer, effective July 6, 2020. VisionCare provides the only FDA approved surgical treatment for macular degeneration, the telescope implant and CentraSight treatment program. “We’re thrilled
- Sight Sciences Names New Chief Operating Officer and General Counselhttps://modernod.com/news/sight-sciences-names-new-chief-operating-officer-and-general-counsel/2477930/Sight Sciences announced two key hires: Sam Park, joining as Chief Operating Officer, and Jeremy Hayden, who joins as General Counsel and Chief Compliance Officer. “We are excited to be able to add leaders with the outstanding track records of Sam and Jeremy as Sight Sciences continu
- NYU Langone Names New Chair of Ophthalmologyhttps://modernod.com/news/nyu-langone-names-new-chair-of-ophthalmology/2477903/Kathryn A. Colby, MD, PhD, an internationally renowned physician–scientist, has been appointed chair of the Department of Ophthalmology at NYU Langone Health. She assumes her new post this fall. Dr. Colby is currently the Louis Block Professor and chair of the Department of Ophthalmology a
- Strategic National Stockpile Aims to Get 400M Syringes by December for COVID-19 Vaccine: Officialshttps://modernod.com/news/strategic-national-stockpile-aims-to-get-400m-syringes-by-december-for-covid-19-vaccine-officials/2477888/Trump administration officials want to stockpile 400 million syringes and needles by December in anticipation of a COVID-19 vaccine, according to a FierceHealthcare report. Administration officials testified before Congress on Tuesday on the procurement of supplies during the COVID-19 pand
- Caren Mason, CEO of Starr Surgical, Named to Top 50 Healthcare Technology CEOs Of 2020https://modernod.com/news/caren-mason-ceo-of-starr-surgical-named-to-top-50-healthcare-technology-ceos-of-2020/2477827/The Healthcare Technology Report announced The Top 50 Healthcare Technology CEOs of 2020. Data on each CEO’s professional background was gathered and they were assessed across several key areas, including breadth of leadership experience in the healthcare technology industry, level of exper
- Clyraguard Shows Complete Inactivation of SARS-CoV-2 Virus in Study at Galveston National Labhttps://modernod.com/news/clyraguard-shows-complete-inactivation-of-sars-cov-2-virus-in-study-at-galveston-national-lab/2477802/Clyra Medical Technologies announced that it has received test results showing that its proprietary copper iodine antimicrobial and antiviral product, Clyraguard, successfully inactivated the COVID-19 coronavirus (SARS-CoV-2 virus). Testing was conducted by the laboratory of Slobodan Paess
- Trump to Name Former GlaxoSmithKline Executive to Head “Warp Speed” Coronavirus Vaccine Effort: Reportshttps://modernod.com/news/trump-to-name-former-glaxosmithkline-executive-to-head-warp-speed-coronavirus-vaccine-effort-reports/2477765/According to White House officials cited in several reports Wednesday, President Donald Trump is expected to appoint Moncef Slaoui, the former chairman of GlaxoSmithKline’s vaccines division, as chief adviser of Operation Warp Speed, an initiative aimed at speeding up the search for a coron